Platelet-to-Lymphocyte Ratio (PLR) Is Not a Predicting Marker of Severity but of Mortality in COVID-19 Patients Admitted to the Emergency Department: A Retrospective Multicenter Study.
COVID-19
PLR
mortality
platelet-to-lymphocyte ratio
severity
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
21 Aug 2022
21 Aug 2022
Historique:
received:
30
07
2022
revised:
18
08
2022
accepted:
19
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
(1) Introduction: In the present study, we investigate the prognostic value of platelet-to-lymphocyte ratio (PLR) as a marker of severity and mortality in COVID-19 infection. (2) Methods: Between 1 March and 30 April 2020, we conducted a multicenter, retrospective cohort study of patients with moderate to severe coronavirus 19 (COVID-19), all of whom were hospitalized after being admitted to the emergency department (ED). (3) Results: A total of 1035 patients were included in our study. Neither lymphocytes, platelets or PLR were associated with disease severity. Lymphocyte count was significantly lower and PLR values were significantly higher in the group of patients who died, and both were associated with mortality in the univariate analysis (OR: 0.524, 95% CI: (0.336−0.815), p = 0.004) and (OR: 1.001, 95% CI: (1.000−1.001), p = 0.042), respectively. However, the only biological parameter significantly associated with mortality in the multivariate analysis was platelet count (OR: 0.996, 95% CI: (0.996−1.000), p = 0.027). The best PLR value for predicting mortality in COVID-19 was 356.6 (OR: 3.793, 95% CI: (1.946−7.394), p < 0.001). (4) Conclusion: A high PLR value is however associated with excess mortality.
Identifiants
pubmed: 36013142
pii: jcm11164903
doi: 10.3390/jcm11164903
pmc: PMC9409988
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1204-12
pubmed: 24793958
Am J Emerg Med. 2021 Feb;40:110-114
pubmed: 33309506
J Thromb Haemost. 2020 Jun;18(6):1469-1472
pubmed: 32302435
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Thromb Res. 2020 Sep;193:110-115
pubmed: 32535232
Med Sci Monit. 2020 Dec 21;26:e927674
pubmed: 33342993
Clin Chem Lab Med. 2020 Jun 25;58(7):1021-1028
pubmed: 32286245
Int J Mol Sci. 2021 Dec 20;22(24):
pubmed: 34948438
J Neuroinflammation. 2021 Feb 20;18(1):51
pubmed: 33610168
Oncotarget. 2016 May 3;7(18):25516-27
pubmed: 27027440
Allergy. 2021 Feb;76(2):533-550
pubmed: 32662525
J Infect Dis. 2020 May 11;221(11):1762-1769
pubmed: 32227123
J Clin Lab Anal. 2020 Oct;34(10):e23566
pubmed: 32914892
Angiology. 2016 Jan;67(1):89-95
pubmed: 25922197
Clin Cardiol. 2021 Jul;44(7):994-1001
pubmed: 34037246
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
J Clin Lab Anal. 2020 Oct;34(10):e23547
pubmed: 32860454
Leukemia. 2020 Aug;34(8):2163-2172
pubmed: 32528042
Epidemiol Infect. 2020 Sep 09;148:e211
pubmed: 32900409
J Med Virol. 2021 Jan;93(1):250-256
pubmed: 32592501
Chin Med J (Engl). 2020 May 5;133(9):1087-1095
pubmed: 32358325
Signal Transduct Target Ther. 2020 Mar 27;5(1):33
pubmed: 32296069
Clin Chim Acta. 2020 Aug;507:174-180
pubmed: 32339487
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
EBioMedicine. 2020 May;55:102763
pubmed: 32361250
Crit Care. 2020 Jun 5;24(1):287
pubmed: 32503670
BMC Infect Dis. 2021 Aug 21;21(1):855
pubmed: 34418980
Ann Lab Med. 2019 Jul;39(4):345-357
pubmed: 30809980
Cell Biol Int. 2020 Sep;44(9):1792-1797
pubmed: 32458561